Introduction

▼
Topiramate is an anticonvulsant approved for the treatment of epilepsy and migraine prophylaxis [ 1 ] . The proposed pharmacological mechanisms of topiramate include a decrement of neuronal excitation, an enhancement of γ-aminobutyric acid (GABA) activity at a non-benzodiazepine site on GABA A receptors, an increase in GABA-mediated chloride channels, a modulation of voltagedependent sodium and calcium channels, a blockade of kainate/AMPA glutamate receptor, and an increase in the potassium conductance [ 2 ] . The effi cacy of topiramate has been reported in several psychiatric conditions, such as psychotic disorders [ 3 , 4 ] , bipolar disorder [ 3 ] , and substance-related disorders [ 3 , 5 ] . Appetite suppression and weight loss are common adverse eff ects in persons treated with topiramate [ 1 -3 ] . In this sense, the pursuit of whether topiramate is a potential weight-loss drug for overweight persons has been the focus of many investigations.
persons with schizophrenia receiving olanzapine therapy, the improved body weight could not be sustained after discontinuing sibutramine, an approved weight-loss drug [ 13 ] . Recently, another study addressing metformin discontinuation reported similar negative fi ndings in non-diabetic patients with schizophrenia treated with clozapine [ 14 ] . Indubitably, the challenge to fi nd an appropriate approach for maintenance of weight loss in schizophrenia remains. So far there are no studies investigating whether and over how long a period weight loss could be sustained after topiramate discontinuation. Only one case report suggested weight rebound after topiramate cessation [ 15 ] . This pilot study aimed to evaluate the overall effi cacy of topiramate for weight management in non-diabetic, overweight individuals with schizophrenia. The study investigating the eff ects of metformin discontinuation recorded body weight only 24 weeks after metformin discontinuation [ 14 ] , rendering the trajectory of weight changes unclear. In our study the primary outcome was the monthly weight changes during topiramate addition and after topiramate discontinuation. The secondary outcome measures included fasting leptin, lipid profi les, insulin resistance index, and adverse eff ects. The null hypothesis of the study was that weight loss produced by topiramate could not be sustained after discontinuing topiramate intervention.
Methods
▼
Participants
From January 2011 to March 2012 a total of 10 individuals with schizophrenia were judged eligible. Participants were recruited from the long-stay ward of the Beitou Branch, Tri-Service General Hospital, National Defense Medical Center, a psychiatric teaching hospital in Taiwan. The Institutional Review Board for the Protection of Human Subjects at the Tri-Service General Hospital approved the protocol. All participants were informed about the aims and other details of the study, and gave written informed consent in accordance with the National Health and Medical Research Council guideline. They were free to withdraw their participation at any time. All participants were older than 20 years of age with a body mass index (BMI) exceeding 27 kg/m 2 , were diagnosed with schizophrenia according to DSM-IV criteria, had been stable on current psychotropics for at least 6 months, and were non-diabetic and normotensive. Additionally, all participants were fully capable of comprehending the study's purpose, procedure, treatment, risk and possible benefi ts, alternative treatment, and their right to refuse to participate in this study. Individuals were excluded if they had a history of another signifi cant medical disorder (e. g., epilepsy); if they met criteria for substance-related disorders; if they had a history of suicidality (attempt or current ideation); if they were involved in a special diet or special physical exercise program for weight reduction; and/or if they had a history of exposure to topiramate, or were currently taking topiramate or other weight-loss drugs. Importantly, individuals who lost more than 5 % of body weight within 3 months were excluded because these persons might be suitable for non-pharmacological interventions for their weight management.
Study design
An open-label, fi xed-dose design was used. This pilot study consisted of 2 stages. [ 17 ] . Serum leptin levels were determined with a sensitive radioimmunoassay and were set into relationship to the BMI-adjusted reference range (log 10 -scaled) of healthy men and women [ 18 ] . Venous blood samples were collected after an overnight fast, between 07.30 h and 09.00 h. Scales for safety included the Udvalg for Kliniske Undersogelser Side Eff ect Rating Scale [ 19 ] and the 17-item Hamilton Depression Rating Scale [ 20 ] . Laboratory measures and scales for safety were assessed at baseline, 4 months after topiramate administration (M 4 ), and 3 months after topiramate discontinuation (M 7 ). All participants underwent measurements of height and weight by a digital weighing scales with height rods. Height was measured to the nearest 0.1 cm (shoes and socks removed). Body weight was measured to the nearest 0.1 kg every month with the participant wearing only a standard T-shirt (double extra large). A trained nurse blinded to the study protocol completed these measurements.
Statistical analyses
All statistical analyses were conducted with the Statistical Package for the Social Science software for Windows (Chicago, IL). Paired sample t-tests were used to evaluate each continuous variable for pre-to post-treatment change. Given that body weight was measured repeatedly on the same individual across time, generalized estimating equations (GEE) were employed, and the fi rst-order autoregressive working correlation structure was chosen. GEE could accommodate the correlation of repeated measurements, account for within-subject dependence eff ects, use all available data points, and be sensitive to patterns of change over time. In the GEE model body weight measured every This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
month was the dependent variable. Independent variables that were entered in the fi nal model included a time eff ect, the baseline body weight, and the dose of antipsychotic that were converted to chlorpromazine equivalents [ 21 ] . Other laboratory measures not identifi ed as covariates were not included in the GEE model, such as age, sex, the dose of lithium and anticholinergic, and the diagnosis of metabolic syndrome according to International Diabetes Federation Task Force Criteria [ 22 ] . The time eff ect implied each month investigation, including 4-month treatment phase (M 0 , M 1 , M 2 , M 3 , and M 4 ) and 12-month followup phase (M 5 , M 6 , M 7 to M 16 ). In addition to the fi rst GEE model examining changes in body weight, a second GEE model was conducted to explore the eff ect of leptin on topiramate-associated weight loss. In the second GEE model, the dependent variable was the body weight, and the independent variables included a time eff ect, leptin levels, baseline body weight, and an interaction eff ect ([time] × [leptin]). The working correlation was fi rst-order autoregression. Body weight changes in the second GEE model included only M 0 , M 1 , M 2 , M 3 , M 4 , and M 7 , as leptin levels were obtained only in these months.
Results
▼
Monthly body weight changes
Overall, topiramate was well tolerated. There were no serious adverse events, and no one discontinued medication due to adverse eff ects. No subject developed suicidal ideation. Of the 10 persons recruited in this pilot study, one patient dropped out on Table 1 .
For controlling the dose of antipsychotic in the GEE model, the dose of each antipsychotic was converted to chlorpromazine equivalents [ 21 ] .
• ▶ Table 2 
Discussion
▼
One of the major diffi culties with treating obesity is that even after initial successful weight loss, most persons relapse into their previous unhealthy eating habits, thereby leading to weight regain. This study represents an attempt to explore, after the discontinuation of topiramate, how long the overweight persons with schizophrenia would maintain their body weight. After the 4-month addition of topiramate 100 mg/d, the participants signifi cantly lost 1.79 kg of their body weight (95 % CI = − 3.03 to − 0.56), and the weight-loss eff ect could be observed from the second month. This fi nding is somewhat similar to those derived from studies addressing the effi cacy of topiramate in the management of overweight persons with schizophrenia [ 9 -11 ] . However, an intriguing, and important, fi nding emerged -even though topiramate had been discontinued, the weight-loss eff ect persisted. The maximum weight reduction was 4.32 kg, occurring when topiramate had been discontinued for 12 months. These fi ndings clearly suggest that weight-loss eff ect could not only persist during topiramate administration but also continued to improve despite topiramate discontinuation. The mechanisms of topiramate-associated weight loss have been discussed in detail elsewhere [ 2 , 11 ] ; in this paper, therefore, we emphasize the possible mechanisms contributing to continuing weight-loss eff ect after topiramate discontinuation. The fi rst mechanism might be attributed to the improvement in leptin resistance. Leptin is the primary adipose hormone that provides adiposity signal to brain, which could result in reducing food intake and increasing energy expenditure [ 23 , 24 ] . Nevertheless, obese persons generally have markedly elevated, rather than decreased, leptin levels. The coexistence of obesity and an unusually high circulating concentration of leptin has been linked to leptin resistance [ 23 -25 ] , a condition similar to insulin resistance. Leptin resistance is an important component in the development and maintenance of obesity [ 23 -25 ] . Additionally, leptin resistance and obesity may aggravate each other, causing a vicious cycle to develop. In this scenario, restoration of leptin functioning might be a therapeutic target to successfully cut off this vicious cycle. An animal study published recently reported the effi cacy of topiramate in improving leptin functioning [ 26 ] . The involved molecular mechanisms are to enhance leptin signaling to the brain and increase hypothalamic expression of anorexigenic neuropeptides. Given leptin resistance as a consequence of defects in leptin signaling and impairment in the hypothalamic neural circuitry [ 23 , 25 ] , topiramate theoretically improves leptin resistance, thereby leading to continued weight loss. The general estimating equations included baseline body weight and leptin levels as covariates b Month 0 is the beginning of topiramate treatment, and Month 7 is the 3-month follow-up after topiramate discontinuation
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Leptin levels (ng/mL) The second mechanism of topiramate responsible for continuing weight-loss eff ect might be related to the modulation of corticomesolimbic dopamine function [ 27 ] . Like alcoholism in which decreased dopamine D 2 receptor availability correlates with cue reactivity and craving [ 28 ] , obese individuals are found to have decreased striatal D 2 receptor availability [ 29 , 30 ] . The reduced basal activity of mesolimbic dopamine system might predispose them to attribute greater incentive salience to food cues, leaving them at more risk for compulsive eating. Several lines of evidence have supported the effi cacy of topiramate in alcohol dependence [ 31 , 32 ] , and regulating cortico-mesolimbic dopamine function is one of the proposed mechanisms [ 27 ] . Therefore, after 4-month treatment with topiramate, the restored mesolimbic dopamine tone might theoretically abate the hyperreactivity of the mesolimbic system toward reward-predicting cues, thus adapting our patient's motivation to eat palatable food.
In our study, after 3 months of topiramate discontinuation, leptin levels were decreased by 84.5 % (4.4 ± 6.7 ng/mL) from a baseline value of 43.3 ± 17 ng/mL. The second GEE model indicated that in addition to baseline body weight, the interaction eff ect of [Month 7] × [leptin] contributed to the main proportion of variance of weight changes. The signifi cant interaction eff ect clear suggests that after topiramate was discontinued for 3 months, the remarked reduction in leptin levels signifi cantly aff ects weight changes. A previous study has reported the association between leptin levels and the percentage of weight decrease in persons with epilepsy taking topiramate [ 2 ] . Namely, persons who reduced more body weight had a more signifi cant reduction of leptin levels after topiramate administration. In this study, the eff ect size for change in leptin levels is large (1.85).
Taking the above points together, continuing weight-loss eff ect after topiramate discontinuation may be associated with the improvement of leptin resistance, the restoration of mesolimbic dopamine function, and the remarked changes in leptin levels. Data from previous studies addressing weight changes after discontinuation of weight-loss agents appear to stand in contrast to our fi ndings. Either sibutramine [ 13 ] or metformin [ 14 ] demonstrates weight regain in obese persons with schizophrenia after their discontinuation. In this study, we hypothesize that topiramate discontinuation-associated continuing weight-loss eff ect results from the potential of topiramate to improve leptin functioning, decrease leptin levels, and restore mesolimbic dopamine function. One may question why metformin or sibutramine could not have continuing weight-loss eff ects after their discontinuation if both drugs do aff ect leptin in a similar way. Evidence suggests that metformin could decrease serum leptin levels [ 33 ] , restore leptin sensitivity [ 34 ] , and increase hypothalamic leptin receptor expression [ 35 ] . In the case of sibutramine, post-treatment leptin levels were decreased in some studies [ 36 , 37 ] , but increased in the other one [ 38 ] . Until now, research has not explored how these 2 weight-loss agents infl uence mesolimbic dopamine system. Moreover, few head-to-head studies have compared the extent to which these 2 drugs aff ect leptin functioning and leptin levels, not to mention the other molecular mechanisms contributing to weight-controlling properties. It is clear that further studies designed in a head-to-head manner into the diff erences among weight-loss agents would be interesting and provide a hint to solve the puzzle. We advise to exercise caution while interpreting the fi ndings from this study. First, our sample size was small, which may have reduced the stability of estimates and led to wide confidence intervals. Based on an alpha of 0.05, a power of 0.8, an eff ect size of 0.665 for weight changes, and a 2-sided paired t -test, a sample size of 20 was determined. In the same manner with an eff ect size of 1.85 for leptin changes, a sample size of 5 was obtained. Evidently, further study using a sample size larger than 20 could confi rm our fi ndings. Second, weight loss was observed from the second month; however, at that time leptin levels were still so high, and the interaction eff ect ([time] × [leptin]) reached signifi cance from the third month. Thus, there may be other underinvestigated mechanisms in this study leading to topiramate's weight-loss eff ect. Indeed, diverse pharmacological mechanisms have been associated with topiramate-induced weight loss [ 2 , 11 ] , such as its antagonistic eff ect on kainite/AMPA glutamate receptor. The third limitation is the fact that although the dose of the antipsychotic had been controlled, the liability among antipsychotics to induced weight gain is distinctly diff erent [ 39 ] . In other words, it remains to be established which kinds of antipsychotic-associated weight gain are most manageable by topiramate. This study included 2 patients treated with the high potential weight gain antipsychotic, clozapine. Fourth, although chronically hospitalized patients might have more consistent activities of daily living and more similar diet contents, this study could be improved if we used eating scale, such as the 3-Factor Eating Questionnaire-R18 [ 40 ] . Assessing the aspects of eating behavior, including cognitive restraint, uncontrolled eating, and emotional eating, provides another approach to disentangle the mechanisms underlying continuing weight loss after topiramate discontinuation. Fifth, leptin levels were obtained until 3-month follow-up after topiramate discontinuation; hence, it is unknown, since that time point, whether the interaction eff ect between topiramate discontinuation and leptin levels could have an impact on weight changes. Finally, the subjects in this study were non-diabetic and normotensive, so the effi cacy of topiramate on weight reduction should be generalized with caution to other populations, such as obese individuals with well-established diabetes.
Maintaining the weight loss is diffi cult to achieve for most persons, and in this respect, it may be even more diffi cult to do for persons with schizophrenia, consisting of negative symptoms and cognitive defi cits as intrinsic parts of illness. This study demonstrates a sustained benefi t of topiramate to reduce body weight in obese persons with schizophrenia. Above all, subjects revealed continued reductions in body weight and leptin levels even after topiramate had been discontinued for 12 months. We suggest, based on previous evidence and our present fi ndings, that continuing weight-loss eff ect after topiramate discontinuation might have resulted from topiramate's potential to improve leptin functioning, decrease leptin levels, and restore mesolimbic dopamine function. We acknowledge that the small sample size and the lack of control group limit the generalizability of the fi ndings. However, this study provides new evidence that in obese persons with schizophrenia, maintenance of weight loss after the discontinuation of weight-loss agents might be possible. To put this in perspective, a better understanding toward the overall mechanisms of topiramate and their interactions with leptin is thus of signifi cant importance. We believe that this pilot study should be replicated because of the encouraging results. Further investigation is necessary to determine the effi cacy of higher doses of topiramate in weight management and its impact on leptin functioning, and to evaluate the potential continuing weightloss eff ect in diff erent populations. This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
